"Pfizer needs to be realistic about its operating environment, embrace necessary changes and turn them to our advantage, for the benefit of our shareholders and everyone with a stake in our future," said Chief Executive Officer Jeffrey B. Kindler.
The company said it expects its restructuring program to yield savings of about $2.5 billion this year, $500 million ahead of earlier projections.
U.S. sales of cholesterol buster Lipitor rose 19% to $2.07 billion from $1.74 billion, helped by higher prices and the new Medicare drug plan. Global sales of Lipitor, the world's top-selling drug, rose 15% to $3.32 billion from $2.9 billion.
Source: Yahoo Finance
Price per share: $28.29
Market Cap (intraday): 206.28B
Enterprise Value (19-Oct-06)3: 199.52B
Trailing P/E (ttm, intraday): 19.18
Forward P/E (fye 31-Dec-07) 1: 13.41
PEG Ratio (5 yr expected): 4.06
Price/Sales (ttm): 4.00
Price/Book (mrq): 2.99
Enterprise Value/Revenue (ttm)3: 3.90
Enterprise Value/EBITDA (ttm)3: 9.09
Profit Margin (ttm): 21.19%
Return on Assets (ttm): 9.19%
Return on Equity (ttm): 16.23%
Why is Pfizer a potential purchase?
1. Many super-investors own Pfizer (Tweedy Browne, Marty Whitman, Arnold Van Den Berg, Bill Miller, etc.) Please visit: GuruFocus.
2. Management is doing the right things of cutting costs, buying back shares, and increasing dividends.
PFE 1-yr chart: